Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model

Immune responses induced by Clostridium difficile

(2016) Séverine Péchiné et al.   ANAEROBE

Vaccine technologies: From whole organisms to rationally designed protein assemblies

(2016) Christopher P. Karch et al.   BIOCHEMICAL PHARMACOLOGY

New and emerging therapies for Clostridium difficile infection

(2016) Jessica Martin et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Breakthroughs in the treatment and prevention of Clostridium difficile infection

(2016) Larry K. Kociolek et al.   Nature Reviews Gastroenterology & Hepatology

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers

(2016) Nicole Bézay et al.   VACCINE

Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects

(2016) Stefano Di Bella et al.   Toxins

Surface charge effect on mucoadhesion of chitosan based nanogels for local anti-colorectal cancer drug delivery

(2015) Chao Feng et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Fecal microbiota transplantation forClostridium difficileinfection: back to the future

(2015) Guglielmo Borgia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Proton-Pump Inhibitor Exposure AggravatesClostridium difficile–Associated Colitis: Evidence From a Mouse Model

(2015) Yuan-Pin Hung et al.   JOURNAL OF INFECTIOUS DISEASES

The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model

(2015) Shanguang Guo et al.   VACCINE

Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections

(2015) Glen P. Carter et al.   mBio

Clostridium difficile: New Insights into the Evolution of the Pathogenicity Locus

(2015) Marc Monot et al.   Scientific Reports

A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity againstClostridium difficileinfection in mice and hamsters

(2015) Yuan-Kai Wang et al.   Human Vaccines & Immunotherapeutics

Immune-based treatment and prevention of Clostridium difficile infection

(2015) Song Zhao et al.   Human Vaccines & Immunotherapeutics

Emergence of a Ribotype 244 Strain of Clostridium difficile Associated With Severe Disease and Related to the Epidemic Ribotype 027 Strain

(2014) S. K. Lim et al.   CLINICAL INFECTIOUS DISEASES

An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody ResponsesIn Vivo

(2014) Scott M. Baliban et al.   INFECTION AND IMMUNITY

Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine

(2014) Kai Zhao et al.   International Journal of Nanomedicine

Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing

(2013) David W. Eyre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response

(2013) Michael Maynard-Smith et al.   VACCINE

Clostridium difficile infection in the community: a zoonotic disease?

(2012) M.P.M. Hensgens et al.   CLINICAL MICROBIOLOGY AND INFECTION

A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection

(2012) Haiying Wang et al.   INFECTION AND IMMUNITY

The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles

(2012) Eleonore Fröhlich   International Journal of Nanomedicine

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

(2012) Jing-Hui Tian et al.   VACCINE

Clostridium difficile: Development of a novel candidate vaccine

(2012) Ginamarie Foglia et al.   VACCINE

Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus

(2012) Ho-Jin Moon et al.   VETERINARY MICROBIOLOGY

Surface Charge Affects Cellular Uptake and Intracellular Trafficking of Chitosan-Based Nanoparticles

(2011) Zhan-Guo Yue et al.   BIOMACROMOLECULES

A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery

(2011) Mei-Chin Chen et al.   BIOMATERIALS

The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells

(2011) Liang Chen et al.   NANOTECHNOLOGY

The role of toxin A and toxin B in the virulence of Clostridium difficile

(2011) Glen P. Carter et al.   TRENDS IN MICROBIOLOGY

A Role for TLR4 in Clostridium difficile Infection and the Recognition of Surface Layer Proteins

(2011) Anthony Ryan et al.   PLoS Pathogens

Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers

(2010) Neeraj Mishra et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

The role of toxin A and toxin B in Clostridium difficile infection

(2010) Sarah A. Kuehne et al.   NATURE

Clostridium difficile infection: epidemiology, risk factors and management

(2010) Ashwin N. Ananthakrishnan   Nature Reviews Gastroenterology & Hepatology

Unmet needs in modern vaccinology

(2010) Geert Leroux-Roels   VACCINE

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

Historical Perspectives on Studies ofClostridium difficileandC. difficileInfection

(2008) John G. Bartlett   CLINICAL INFECTIOUS DISEASES

Bile Salts and Glycine as Cogerminants for Clostridium difficile Spores

(2008) J. A. Sorg et al.   JOURNAL OF BACTERIOLOGY